Literature DB >> 15784562

Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens.

Caroline Demangel1, Thierry Garnier, Ida Rosenkrands, Stewart T Cole.   

Abstract

In silico analysis reveals that most protective antigens expressed by the antituberculous vaccine Mycobacterium bovis BCG (BCG) are conserved in M. avium, supporting the hypothesis that exposure to environmental mycobacteria generates cross-reactive immune responses blocking BCG activity. We investigated the impact of sensitization with M. avium, M. scrofulaceum, or M. vaccae on the protective efficacy of a recombinant BCG strain expressing RD1 antigens (BCG::RD1), using a mouse model of experimental tuberculosis (TB). No evidence that the RD1-encoded antigens ESAT-6, CFP-10, and PPE68 were expressed by these environmental strains could be demonstrated by Western blot analysis. Mice sensitized with each of these strains did not prime cellular immune responses cross-reacting with the immunodominant ESAT-6. Importantly, clearance of BCG::RD1 from the lungs and spleens of mice exposed to each of the environmental strains before vaccination was minimal compared to that of BCG. In mice sensitized with M. avium, increased persistence of BCG::RD1 correlated with stronger antimycobacterial gamma interferon responses and enhanced protection against aerosol infection with M. tuberculosis, compared to BCG. In contrast, animals exposed to M. scrofulaceum or M. vaccae prior to vaccination with BCG or BCG::RD1 were better protected against TB than were the unsensitized controls. Our results suggest that the inhibitory effect of environmental mycobacteria on the protective efficacy of BCG depends critically on the extent of cross-recognition of antigens shared with the vaccine. In hosts sensitized with M. avium, potent immunogenicity of ESAT-6 and increased persistence of BCG::RD1 may allow this recombinant vaccine to overcome preexisting antimycobacterial responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784562      PMCID: PMC1087454          DOI: 10.1128/IAI.73.4.2190-2196.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.

Authors:  Alexander S Pym; Priscille Brodin; Roland Brosch; Michel Huerre; Stewart T Cole
Journal:  Mol Microbiol       Date:  2002-11       Impact factor: 3.501

2.  Efficacy of bacillus Calmette-Guérin and isoniazid-resistant bacillus Calmette-Guérin with and without isoniazid chemoprophylaxis from day of vaccination. II. Field trial in man.

Authors:  H M Vandiviere; M Dworski; I G Melvin; K A Watson; J Begley
Journal:  Am Rev Respir Dis       Date:  1973-08

3.  Immunological characterization of antigens encoded by the RD1 region of the Mycobacterium tuberculosis genome.

Authors:  P N Brusasca; R Colangeli; K P Lyashchenko; X Zhao; M Vogelstein; J S Spencer; D N McMurray; M L Gennaro
Journal:  Scand J Immunol       Date:  2001-11       Impact factor: 3.487

4.  Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex.

Authors:  E Lozes; K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; P Vandenbussche; J P Van Vooren; A Drowart; J B Ulmer; M A Liu
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

5.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 6.  BCG: the challenge continues.

Authors:  P E Fine
Journal:  Scand J Infect Dis       Date:  2001

7.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.

Authors:  P D Hart; I Sutherland
Journal:  Br Med J       Date:  1977-07-30

8.  The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue.

Authors:  Tsungda Hsu; Suzanne M Hingley-Wilson; Bing Chen; Mei Chen; Annie Z Dai; Paul M Morin; Carolyn B Marks; Jeevan Padiyar; Celia Goulding; Mari Gingery; David Eisenberg; Robert G Russell; Steven C Derrick; Frank M Collins; Sheldon L Morris; C Harold King; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

9.  Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system.

Authors:  Sarah A Stanley; Sridharan Raghavan; William W Hwang; Jeffery S Cox
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

10.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  27 in total

1.  Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.

Authors:  Timothy Lahey; Robert D Arbeit; Muhammad Bakari; C Robert Horsburgh; Mecky Matee; Richard Waddell; Lillian Mtei; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

Review 2.  Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens.

Authors:  Aarti Rana; Shweta Thakur; Girish Kumar; Yusuf Akhter
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

Review 3.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

4.  Genome plasticity of BCG and impact on vaccine efficacy.

Authors:  Roland Brosch; Stephen V Gordon; Thierry Garnier; Karin Eiglmeier; Wafa Frigui; Philippe Valenti; Sandrine Dos Santos; Stéphanie Duthoy; Céline Lacroix; Carmen Garcia-Pelayo; Jacqueline K Inwald; Paul Golby; Javier Nuñez Garcia; R Glyn Hewinson; Marcel A Behr; Michael A Quail; Carol Churcher; Bart G Barrell; Julian Parkhill; Stewart T Cole
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

5.  Environmental strains of Mycobacterium avium interfere with immune responses associated with Mycobacterium bovis BCG vaccination.

Authors:  Sarah L Young; Lynn Slobbe; Rachel Wilson; Bryce M Buddle; Geofferey W de Lisle; Glenn S Buchan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

Review 6.  Tuberculosis: what we don't know can, and does, hurt us.

Authors:  David G Russell; Clifton E Barry; JoAnne L Flynn
Journal:  Science       Date:  2010-05-14       Impact factor: 47.728

7.  Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.

Authors:  Birgit Korioth-Schmitz; Casey C Perley; Jaimie D Sixsmith; Eva M Click; Sunhee Lee; Norman L Letvin; Richard Frothingham
Journal:  Vaccine       Date:  2015-07-17       Impact factor: 3.641

8.  Different immunosuppressive mechanisms in multi-drug-resistant tuberculosis and non-tuberculous mycobacteria patients.

Authors:  R O Pinheiro; E B de Oliveira; G Dos Santos; G M Sperandio da Silva; B J de Andrade Silva; R M B Teles; A Milagres; E N Sarno; M P Dalcolmo; E P Sampaio
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

9.  Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.

Authors:  Antonia Isabel Castillo-Rodal; Mauricio Castañón-Arreola; Rogelio Hernández-Pando; Juan José Calva; Eduardo Sada-Díaz; Yolanda López-Vidal
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria.

Authors:  May Young Lin; T B K Reddy; Sandra M Arend; Annemieke H Friggen; Kees L M C Franken; Krista E van Meijgaarden; Marleen J C Verduyn; Gary K Schoolnik; Michel R Klein; Tom H M Ottenhoff
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.